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thetic lethal” small molecule screen allowed for the iden-Finding Cinderella after the Ball:
tification of proteins and pathways in yeast that areA Three-Hybrid Approach involved in DNA synthesis and repair [2]. Borrowing
from a traditional genetic approach, the small moleculesto Drug Target Identification
camptothecin and hydroxyurea were screened for le-
thality against a library of single-knockout mutants in
yeast. Uncharacterized open reading frames involved in
DNA repair were then inferred by comparing the small
A major bottleneck in drug discovery is identifying molecules’ patterns of lethality to those of all double
the targets of small molecules. The yeast three-hybrid mutants. Alternatively, Snyder and coworkers used pro-
assay extends the two-hybrid approach to screen for tein chip technology to print the 6000 proteins found
protein-small molecule interactions. In this issue of in S. cerevisiae on glass slides and assay them for bind-
Chemistry & Biology, GPC Biotech reports the first ing to phospholipids [3].
application of this promising assay [11]. In 1996, Licitra and Liu extended high-throughput
yeast two-hybrid methods to small molecule target iden-
tification [4]. In the two-hybrid assay, protein-proteinDrug developers face a problem similar to that of the
interactions are detected as reconstitution of a tran-Prince in the Cinderella story. They have a small mole-
scriptional activator from its DNA binding (DBD) andcule that produces the desired physiological response,
activation domains (AD) [5]. The assay can be run on abut they do not know the protein target to which the
genome-wide scale by creating a library of activationsmall molecule binds, the Cinderella who fits the glass
domain-cDNA clones [6]. The three-hybrid assay ex-slipper. Traditionally, the protein targets of small mole-
tends this approach to small molecule-protein interac-cule ligands have been identified using in vitro methods
tions by dimerization of two receptor proteins via asuch as affinity chromatography and photoaffinity label-
bridging heterodimeric ligand [7] (Figure 1). One ligand-ing. The ligand is derivatized so that it can be linked to
receptor pair serves as an anchor, while the other ligand-a resin or photoreactive group. The modified ligand is
receptor pair is the small molecule-protein interactionthen incubated with a crude cell lysate, and the labeled
of interest. As a proof of principle, Licitra and Liu usedprotein is finally identified by N-terminal sequencing.
a dexamethasone-FK506 heterodimer to isolate FK506-These methods have been integral to target discovery,
binding protein 12, the known target of FK506, from abut they are laborious and subject to low protein expres-
Jurkat cDNA library. This approach allows the cDNAsion levels, protein degradation during cell lysis, or insuf-
clones to be expressed at uniformly high levels andficient affinity for the small molecule ligand.
without the need for purification, and the target protein’sGenomics and proteomics are beginning to provide
identity to be simply read out from the cDNA-AD se-real alternatives to these traditional methods for drug
quence at the end of the selection. Despite obvioustarget identification. Expression profiling using DNA mi-
applications for drug discovery, however, there were nocroarrays enabled the identification of the microbial pro-
further reports of using the three-hybrid assay for targettein and pathway targets for isoniazid, the primary drug
discovery beyond this proof of principle experiment.used to treat tuberculosis [1], and potential mechanisms
of resistance. A complementary approach using a “syn- One thought was that the affinity of the ligand-recep-
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Figure 1. Three-Hybrid Assay
The three-hybrid assay offers a potentially powerful tool for drug target identification. Two- and three-hybrid assays detect protein interactions
based on reconstitution of a transcriptional activator from a DNA binding (DBD) and activation (AD) domain. The three-hybrid assay extends
this approach to small molecule-protein interactions by dimerization of two receptor proteins via a heterodimeric ligand. For drug target
identification, as illustrated here, one ligand-receptor pair (methotrexate and DHFR) serves as the anchor, while the other is the drug target
of interest (PurB and CDK). The heterodimeric ligand (Mtx-PurB) can then be screened against a library of AD-cDNA clones. The reporter
gene will only be activated in cells expressing a cDNA to which the drug (PurB) binds.
tor anchor pair (dexamethasone-glucocorticoid recep- the transcription readout relates to the strength of the
ligand-receptor interaction. Drug discovery happens nottor in Licitra and Liu [4]) was limiting the sensitivity of
through a single technique, but by bringing together athe three-hybrid assay and hence its ability to detect
host of techniques to bear on the problem. Perhaps thea variety of ligand-receptor interactions. Thus, several
three-hybrid assay can add to the existing methodolo-groups developed ligand-receptor anchors intended to
gies and speed the search for Cinderella.increase the sensitivity of the assay. Our laboratory de-
veloped an anchor based on the low picomolar interac-
tion between methotrexate and dihydrofolate reductase
Scott Lefurgy1 and Virginia Cornish2[8]. Peterson has now developed anchors based on es-
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Deoxyepothilone B (Sloan-Kettering/Kosan/Roche) andWhat Makes Epothilones Stick?
C21-amino epothilone B (BMS) have also entered clini-
cal trials [12].
Previous authors have made extensive studies of the
SAR of the epothilones, as summarized in the reviewsThe potent epothilone tubulin polymerization promot-
cited [9,10]. The study by Buey et al. [13] goes beyonders have been studied extensively by synthetic and
these studies to provide an in-depth look at why certainSAR approaches. The paper by Buey et al. ([13], this
structural modifications result in increased activity andissue of Chemistry & Biology) adds a new depth of
why others give reduced activity. The authors do thismechanistic understanding by a careful analysis of the
by a careful analysis of the binding affinity of epothilonetubulin polymerization mechanism of the epothilones.
analogs to microtubules and by correlating this affinity
with cytotoxicity. This paper is thus the first in whichThe discovery in 1979 of the ability of paclitaxel (Taxol)
the microtubule binding of epothilones has been studiedto promote the polymerization of tubulin heterodimers
at a fundamental level.to microtubules [1] marked a turning point in the devel-
The major problem with studies of the interaction ofopment of this compound as an anticancer agent, and
paclitaxel and paclitaxel-like compounds with tubulin isit went on to become a blockbuster drug. Paclitaxel’s
that they are too good at what they do. They bind tosuccess initiated a search for other anticancer agents
the polymerized form of tubulin and immediately inducethat operate by the same mechanism, and several com-
further assembly so that it is not possible to study tubulinpounds that do this have been found, including discod-
binding apart from microtubule assembly; the two reac-ermolide [2], eleutherobin [3], and several other natural
tions are inseparably linked. The present authors haveproducts. Of all the “paclitaxel-like” compounds found
previously developed a way around this difficulty by theto date, however, the epothilones have excited the most
use of microtubules stabilized by gentle crosslinkinginterest. Epothilones A (Figure 1[1]) and B (Figure 1[2])
and by the use of fluorescent paclitaxel probes. Thesewere originally isolated as antifungal agents, but scien-
conditions allow the study of the ligand-microtubule in-tific interest in them was enormously stimulated by the
teraction at low enough concentrations to obtain directdiscovery of their tubulin-polymerization activity in 1995
measurements of the binding affinity, and nonfluores-[4] and by the publication of their complete structure
cent ligands can be studied by competition with theand stereochemistry [5]. Biological studies of the epothi-
fluorescent probes.lones have shown that they stabilize microtubules in the
In the present study, the authors applied these meth-same way that paclitaxel does but with somewhat higher
ods to the study of the binding of epothilones A and Bpotencies. Not only do they act as tubulin-polymeriza-
and various epothilone analogs to microtubules. Directtion agents in the same way that paclitaxel does, but
binding constants were calculated, and the reactionsthey also compete for the same binding site on the
were carried out at various temperatures so that Hpolymer, since they act as competitive inhibitors of the
and S values could be calculated for each ligand. Thebinding of [3H]paclitaxel to tubulin polymers [6]. In addi-
binding affinity results are presented graphically in ation, epothilone B has been shown to be superior to
paclitaxel in treating vinblastine-resistant CCRF-CEM
tumors in the mouse [7], and desoxyepothilone B is
curative against paclitaxel-resistant CCRF-CEM tumors
[8]. Several total and partial syntheses of the epothilones
and their analogs have been reported, and extensive
SAR studies have been carried out. Their chemistry and
biology have been reviewed, with two important reviews
by one of the coauthors of the present paper [9, 10].
Epothilone B is the most potent antiproliferative agent
among the naturally occurring tubulin polymerization
promoters, with an activity from 2- to 10-fold greater
than that of paclitaxel, and it is less susceptible than
paclitaxel to Pgp- mediated MDR [11]. Epothilone B is
Figure 1. Epothilones A and Bin phase II trials by Novartis, and its lactam analog BMS-
247550 is in phase II/III trials by Bristol-Myers Squibb. Structures of Epothilone A and Epothilone B.
